Latest news

Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Debiopharm joins discussions with international health organisations to fight anti-microbial resistance at the 2023 World AMR Congress

Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach

Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study